Cargando…

Suboptimal Dosing Parameters as Possible Factors in the Negative Phase III Clinical Trials of Progesterone for Traumatic Brain Injury

To date, outcomes for all Phase III clinical trials for traumatic brain injury (TBI) have been negative. The recent disappointing results of the Progesterone for the Treatment of Traumatic Brain Injury (ProTECT) and Study of a Neuroprotective Agent, Progesterone, in Severe Traumatic Brain Injury (Sy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Howard, Randy B., Sayeed, Iqbal, Stein, Donald G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc. 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455214/ https://www.ncbi.nlm.nih.gov/pubmed/26370183 http://dx.doi.org/10.1089/neu.2015.4179

Ejemplares similares

Progesterone in traumatic brain injury: time to move on to phase III trials
por: Vandromme, Marianne, et al.
Publicado: (2008)

Genomic profile of Toll-like receptor pathways in traumatically brain-injured mice: effect of exogenous progesterone
por: Hua, Fang, et al.
Publicado: (2011)

Progesterone Treatment Shows Benefit in a Pediatric Model of Moderate to Severe Bilateral Brain Injury
por: Geddes, Rastafa I., et al.
Publicado: (2014)

Progesterone Treatment Shows Benefit in Female Rats in a Pediatric Model of Controlled Cortical Impact Injury
por: Geddes, Rastafa I., et al.
Publicado: (2016)

Embracing failure: What the Phase III progesterone studies can teach about TBI clinical trials
por: Stein, Donald G.
Publicado: (2015)

Is progesterone a worthy candidate as a novel therapy for traumatic brain injury?
por: Stein, Donald G.
Publicado: (2011)

Progesterone Attenuates Stress-Induced NLRP3 Inflammasome Activation and Enhances Autophagy Following Ischemic Brain Injury
por: Espinosa-Garcia, Claudia, et al.
Publicado: (2020)

Neuroprotection by Estrogen and Progesterone in Traumatic Brain Injury and Spinal Cord Injury
por: Brotfain, Evgeni, et al.
Publicado: (2016)

The neuroprotective effects of progesterone on traumatic brain injury: current status and future prospects
por: Wei, Jing, et al.
Publicado: (2013)

Progesterone modulates mTOR in the hippocampus of mice after traumatic brain injury
por: Garling, Richard Justin, et al.
Publicado: (2018)

Novel progesterone receptors: neural localization and possible functions
por: Petersen, Sandra L., et al.
Publicado: (2013)

Subcutaneous Progesterone Is Effective and Safe for Luteal Phase Support in IVF: An Individual Patient Data Meta-Analysis of the Phase III Trials
por: Doblinger, Jakob, et al.
Publicado: (2016)

Progesterone treatment reduces neuroinflammation, oxidative stress and brain damage and improves long-term outcomes in a rat model of repeated mild traumatic brain injury
por: Webster, Kyria M., et al.
Publicado: (2015)

Progesterone for Acute Traumatic Brain Injury: A Systematic Review of Randomized Controlled Trials
por: Zeng, Yunhui, et al.
Publicado: (2015)

Suboptimal Dosing of β-Blockers in Chronic Heart Failure: A Missed Opportunity?
por: McGinlay, Melanie, et al.
Publicado: (2022)

The Synergistic Effect of Combination Progesterone and Temozolomide on Human Glioblastoma Cells
por: Atif, Fahim, et al.
Publicado: (2015)

Comparison of the administration of progesterone versus progesterone and vitamin D in improvement of outcomes in patients with traumatic brain injury: A randomized clinical trial with placebo group
por: Aminmansour, Bahram, et al.
Publicado: (2012)

Progesterone Treatment Attenuates Glycolytic Metabolism and Induces Senescence in Glioblastoma
por: Atif, Fahim, et al.
Publicado: (2019)

Mechanism of Progesterone in Treatment of Traumatic Brain Injury Based on Network Pharmacology and Molecular Docking Technology
por: Zheng, Chen, et al.
Publicado: (2022)

Progesterone metabolites regulate induction, growth, and suppression of estrogen- and progesterone receptor-negative human breast cell tumors
por: Wiebe, John P, et al.
Publicado: (2013)

Progesterone suppresses triple-negative breast cancer growth and metastasis to the brain via membrane progesterone receptor α
por: Zhou, Li, et al.
Publicado: (2017)

Patients’ administration preferences: progesterone vaginal insert (Endometrin®) compared to intramuscular progesterone for Luteal phase support
por: Beltsos, Angeline N, et al.
Publicado: (2014)

Effects of an amylopectin and chromium complex on the anabolic response to a suboptimal dose of whey protein
por: Ziegenfuss, T. N., et al.
Publicado: (2017)

Emicizumab dose up‐titration in case of suboptimal bleeding control in people with haemophilia A
por: Schmitt, Christophe, et al.
Publicado: (2022)

Phase III trial of 8% vaginal progesterone gel for luteal phase support in Japanese women undergoing in vitro fertilization and fresh embryo transfer cycles
por: Kokeguchi, Shoji, et al.
Publicado: (2016)

A phase 2 study of intraperitoneal carboplatin plus intravenous dose-dense paclitaxel in front-line treatment of suboptimal residual ovarian cancer
por: Hasegawa, Kosei, et al.
Publicado: (2020)

Improved spatial memory, neurobehavioral outcomes, and neuroprotective effect after progesterone administration in ovariectomized rats with traumatic brain injury: Role of RU486 progesterone receptor antagonist
por: Amirkhosravi, Ladan, et al.
Publicado: (2021)

Efficacy of progesterone for moderate to severe traumatic brain injury: a meta-analysis of randomized clinical trials
por: Lin, Chao, et al.
Publicado: (2015)

Does progesterone show neuroprotective effects on traumatic brain injury through increasing phosphorylation of Akt in the hippocampus?
por: Garling, Richard Justin, et al.
Publicado: (2014)

Progesterone Sharpens Temporal Response Profiles of Sensory Cortical Neurons in Animals Exposed to Traumatic Brain Injury
por: Allitt, Benjamin J., et al.
Publicado: (2017)

Progesterone Provides the Pleiotropic Neuroprotective Effect on Traumatic Brain Injury Through the Nrf2/ARE Signaling Pathway
por: Zhang, Mei, et al.
Publicado: (2016)

Indications for suboptimal low-dose direct oral anticoagulants for non-valvular atrial fibrillation patients
por: Umei, Masahiko, et al.
Publicado: (2017)

Bone marrow concentrate promotes bone regeneration with a suboptimal-dose of rhBMP-2
por: Egashira, Kazuhiro, et al.
Publicado: (2018)

Analysis of Memory B-Cell Responses Reveals Suboptimal Dosing Schedule of a Licensed Vaccine
por: Scherer, Erin M, et al.
Publicado: (2018)

High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence
por: Zamor, Philippe J., et al.
Publicado: (2021)

Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases
por: Ferri, Clodoveo, et al.
Publicado: (2022)

Preoperative Lymphocyte-Monocyte Ratio Is a Predictor of Suboptimal Cytoreduction in Stage III-IV Epithelial Ovarian Cancer
por: Eo, Wankyu, et al.
Publicado: (2016)

Possible significance of degeneration and decreased expression of progesterone receptor in postmenopausal uterine leiomyoma
por: Tanioka, Saki, et al.
Publicado: (2022)

Progesterone receptors - animal models and cell signalling in breast cancer: Diverse activation pathways for the progesterone receptor: possible implications for breast biology and cancer
por: Lanari, Claudia, et al.
Publicado: (2002)

High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial
por: Vliek, Sonja, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_418f158dpro4t2di6olqnuatim